nach oben

PharmacoEconomics

Erschienen in:

01.03.2001 | Review Article

Workplace Productivity

A Review of the Impact of Migraine and its Treatment

verfasst von: Dr Paul Stang, Roger Cady, Alice Batenhorst, Lynn Hoffman

Erschienen in: PharmacoEconomics | Ausgabe 3/2001

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a common disorder characterised by recurrent episodes of disability. Despite the high prevalence of migraine, data have been lacking on its impact in a working population. The advent of new therapies has stimulated interest in this area, and evidence is now available that documents the substantial impact of migraine on workplace productivity and the likelihood of untreated migraine leading to unemployment or underemployment for the patient.

This paper reviews current findings of both observational and interventional studies about the impact of migraine on productivity and employment. When considered in the light of migraine demographics, the high prevalence of migraine, and its low consultation and treatment rates, this evidence indicates that improved screening and treatment for this common condition could have a substantial impact on worker productivity and on patient well-being.

Ettner S, Frank R, Kessler RC. The impact of psychiatric disease on labor market outcomes. Ind Labor Relat Rev 1997; 51: 64–81CrossRef

Conti DJ, Burton WN. The economic impact of depression in the workplace. J Occup Med 1994; 36: 983–8PubMed

Greenberg PE, Kessler RC, Nells TL, et al. Depression in the workplace: an economic perspective. In: Feighner JP, Boyers WF, editors. Selective serotonin reuptake inhibitors: advances in basic research and clinical practice. 2nd ed. Chichester: Wiley, 1996: 321–58

Greenberg PE, Finklestein SN, Berndt ER. Economic consequences of illness in the workplace. Sloan Manage Rev 1995; 36: 26–38

Blau JN. Adult migraine: the patient observed. In: Blau JN, editor. Migraine: clinical and research aspects. Baltimore (MD): Johns Hopkins University Press, 1987: 3–17

Cady RK. Diagnosis and treatment of migraine. Clin Cornerstone 1999; 1 (6): 21–32PubMedCrossRef

Luciani R, Carter D, Mannix L, et al. Prevention of migraine during prodrome with naratriptan. Cephalalgia 2000; 20: 122–6PubMedCrossRef

Griffin NJ, Lipton RB, Silberstein SD, et al. Electronic diary study of premonitory symptoms in migraine. Presented at Headache World 2000; 2000 Sep 6; London

Farmer KU, Cady RK, Bleiberg J, et al. A pilot study to measure cognitive efficiency during migraine. Headache 2000; 40: 657–61 [See also Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: results of an open label study. Headache. In press]PubMedCrossRef

10.

Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized migraine headache in a United States population. Neurology 1999; 53: 1468–73PubMedCrossRef

11.

Lipton RB, Stewart WF, Cady RK, et al. Sumatriptan for the range of headaches in migraine sufferers: results of the SPECTRUM Study. Headache 2000; 40: 783–91PubMedCrossRef

12.

Cady RK, Lipton RB, Hall C, et al. The treatment of mild headache in disabled migraine sufferers: results of the spectrum study. Headache 2000; 40: 792–7PubMedCrossRef

13.

Cady RK, Sheftell F, Lipton RB. Effect of early intervention with sumatriptan on migraine pain: retrospective analysis of data from three clinical trials. Clin Ther 2000; 49: 1035–48CrossRef

14.

Becker G. Human capital. 3rd ed. Chicago (IL): Chicago University Press, 1993

15.

Rice DP. Estimating the cost of illness. Washington, DC: US Government Printing Office, 1966: 20–39 (Health Economics Series No. 6, Public Health Service)

16.

Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89PubMedCrossRef

17.

Wen CP, Tsai SP, Gibson RL. Anatomy of the healthy worker effect: a critical review. J Occup Med 1983; 25: 283–9PubMed

18.

Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. Epidemiol Rev 1988; 10: 87–121PubMed

19.

Stang PE, Osterhaus JT, Celentano DD. Migraine: patterns of health care utilization. Neurology 1994; 44 Suppl. 4: S47–S55PubMed

20.

de Lissovoy G, Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology 1994; 44 (6 Suppl. 4): S56–S62PubMed

21.

Solomon GD, Price KL. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997; 11 Suppl. 1: 1–10PubMedCrossRef

22.

Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998; 13 (6): 667–76PubMedCrossRef

23.

Fishman P, Von Korff M, Lozano P, et al. Chronic care costs in managed care. Health Aff (Millwood) 1997 May–Jun; 16 (3): 239–47CrossRef

24.

Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28 (5): 659–64PubMed

25.

Osterhaus JT, Gutterman DL, Platchetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2 (1): 67–76PubMedCrossRef

26.

Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther 1999; 21: 190–204PubMedCrossRef

27.

The HCUP-3 Nationwide Inpatient Sample, Release 3. US Agency for Health Care Policy and Research, 1994 [online]. Available from: URL: http://www.informatics-online.com [Accessed 2000 May 1]

28.

Stang PE, VonKorff M, Galer BS. Reduced labor force participation among primary care patients with headache. J Gen Intern Med 1998; 13: 296–302PubMedCrossRef

29.

Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia 1999; 19: 50–7PubMedCrossRef

30.

Von Korff M, Stang P. Prediction of the psychosocial and behavioral outcomes of headache in primary care. In: Oleson J, editor. Headache classification and epidemiology. New York (NY): Raven Press, 1995: 367–71

31.

Von Korff M, Ormel J, Keefe FJ, et al. Grading the severity of chronic pain. Pain 1992; 50: 133–49CrossRef

32.

Stewart WF, Lipton RB, Simon D, et al. Validity of an illness severity measure for headache in a population sample of migraine suffers. Pain 1999; 79: 291–301PubMedCrossRef

33.

Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache suffers. Cephalalgia 1999; 19: 107–14PubMedCrossRef

34.

Stang PE, Yanagihara T, Swanson JW, et al. The incidence of migraine headaches: a population-based study in Olmsted County, MN. Neurology 1992; 42: 1657–62PubMedCrossRef

35.

Centers for Diseases Control. Prevalence of chronic migraine headaches — United States, 1980–1989. MMWR Morb Mortal Wkly Rep 1991; 40: 331–8

36.

Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33 (1): 29–35PubMedCrossRef

37.

Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159; 813–8PubMedCrossRef

38.

Blau FD. Trends in the well-being of American women, 1970–1995. Cambridge (MA): National Bureau of Economic Research, 1997. Working Paper No. W6206.

39.

Stang PE, Osterhaus JT. The epidemiology of migraine headache. In: Cady R, Fox A, editors. Treating the headache patient. New York (NY): Marcel Dekker, 1994: 41–60

40.

Breslau N. Psychiatric comorbidity in migraine. Cephalalgia 1998; 18 Suppl. 22: 56–8PubMed

41.

Kessler RC, Frank RG. The impact of psychiatric disorders on work loss days. Psychol Med 1997; 27: 861–73PubMedCrossRef

42.

Dartigues JF, Michel P, Lindoulsi A, et al. Comparative view of the socioeconomic impact of migraine versus low back pain. Cephalalgia 1998; 18 Suppl. 21: 26–9PubMed

43.

Durham CF, Alden KR, Dalton JA, et al. Quality of life and productivity in nurses reporting migraine. Headache 1998; 38 (6): 427–35PubMedCrossRef

44.

Kryst S, Scherl E. A population-based survey of the social and personal impact of headache. Headache 1994; 34 (6): 344–50PubMedCrossRef

45.

Wagner TH, Patrick DL, Galer BS, et al. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache 1996; 36: 484–92PubMedCrossRef

46.

Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American Migraine Study. Cephalalgia 1996; 16: 231–8PubMedCrossRef

47.

Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. Occup Environ Med 1997; 39: 320–7CrossRef

48.

Von Korff M, Stewart WF, Simon DJ, et al. Migraine and reduced work performance: a population-based diary study. Neurology 1998; 50 (6): 1741–5CrossRef

49.

Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilization of medical services: a Danish population study. J Epidemiol Community Health 1992; 46: 443–6PubMedCrossRef

50.

Parry TG. The prevalence and costs of migraine in Australia. Center for Applied Economic Research Working Paper 1992/1. Sydney: University of New South Wales, 1992

51.

Pryse-Phillips W, Findlay H, Tugwell P, et al. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension-type headache, part II. Can J Neurol Sci 1992; 19: 333–9PubMed

52.

Mounstephen AH, Harrison RK. A study of migraine and its effects in a working population. Occup Med 1995; 45: 311–7CrossRef

53.

Michel P, Dartigues JF, Lindoulsi A, et al. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 1997; 37 (2): 71–8PubMedCrossRef

54.

Cortelli P, Dahlof C, Bouchard J, et al. A multinational investigation of the impact of subcutaneous sumatriptan: III. Workplace productivity and nonworkplace productivity. Pharmacoeconomics 1997; 11 Suppl. 1: 35–42PubMedCrossRef

55.

Legg RF, Sclar DA, Nemec NL, et al. Cost benefit of sumatriptan to an employer. J Occup Environ Med 1997; 39 (7): 652–7PubMedCrossRef

56.

Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm 1996; 53 (6): 633–8PubMed

57.

Lofland JH, Johnson NE, Batenhorst AS, et al. Changes in resource use and outcomes for patients with migraine treated with sumatriptan. Arch Intern Med 1999; 159: 857–63PubMedCrossRef

58.

Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996; 36 (3): 137–43PubMedCrossRef

59.

Miller DW, Martin BC, Loo CM. Sumatriptan and lost productivity time: a time series analysis of diary data. Clin Ther 1996; 18 (6): 1263–75PubMedCrossRef

60.

Jhingran P, Cady RK, Rubino J, et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996; 42 (1): 36–42PubMed

61.

Adelman JR, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Manag Care 1996; 2: 1407–16

62.

Cady RK, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998; 158 (9): 1013–8PubMedCrossRef

63.

Cady RK. Reduction of labor costs associated with treating migraine in the workplace [letter]. Arch Intern Med 1999; 159: 197PubMedCrossRef

64.

Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34: 337–43PubMedCrossRef

65.

Solomon GD. Evolution of the measurement of quality of life in migraine. Neurology 1997; 48 Suppl. 3: S10–S15PubMedCrossRef

66.

Dahlof C, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan: II. Health related quality of life. Pharmacoeconomics 1997; 11 Suppl. 1: 24–34PubMedCrossRef

67.

Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996; 28: 171–7PubMed

68.

Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998; 38: 87–96PubMedCrossRef

69.

Stang PE, Von Korff M. The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache 1994; 34: 138–42PubMedCrossRef

70.

Sauter SL, Lim S-Y, Murphy LR. Organizational health: a new paradigm for occupational stress research. Jpn J Occup Ment Health 1996; 4248–54

71.

Warshaw LJ, Burton WN. Cutting the costs of migraine: role of the employee health unit. J Occup Environ Med 1998; 40 (11): 943–53PubMedCrossRef

72.

Warshaw LJ, Burton WN, Silberstein SD, et al. Migraine: a problem for employers and managed care plans. Am J Manage Care 1997; 3: 1515–23

Titel: Workplace Productivity
A Review of the Impact of Migraine and its Treatment
verfasst von: Dr Paul Stang
Roger Cady
Alice Batenhorst
Lynn Hoffman
Publikationsdatum: 01.03.2001
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 3/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200119030-00002

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Workplace Productivity

A Review of the Impact of Migraine and its Treatment

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2001

Cost-Benefit Analysis of Active Vaccination Campaigns Against Hepatitis A Among Daycare Centre Personnel in Israel

Rivastigmine

Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients

Influenza

Cost Effectiveness of Emedastine versus Levocabastine in the Treatment of Allergic Conjunctivitis in 7 European Countries

Economic Burden of Chronic Obstructive Pulmonary Disease